Veru (VERU) PT Lowered to $25 at Oppenheimer, but Reiterated as Top Pick, "Stock Offers Desirable Profile Among Small Caps"

Oppenheimer analyst Leland Gershell lowered the price target on Veru, Inc. (NASDAQ: VERU) to $25.00 (from $26.00) while maintaining a Outperform rating.

The analyst quotes: "As enrollment in VERU's advanced breast and prostate cancer registration trials continue, in 1H22 we look forward to two near-term catalysts: sabizabulin's Phase 3 data in hospitalized COVID-19 patients at high risk for ARDS and Phase 2 results on long-acting GnRH antagonist VERU-100 in hormone-sensitive prostate cancer. LLY collaboration for soon-to-start Phase 3 breast cancer combo trial sets an intriguing stage given enobosarm's ability to restore CDK4/6i sensitivity. Commercial division to start benefiting from high-margin Entadfi revenue, which may have $150–200M potential over time. We reiterate VERU as a top pick and see this name as offering a particularly desirable profile among small cap biopharmas in the current environment."

Written by Vlad Schepkov | [email protected]

You May Also Be Interested In

• Enhanced Group Inc. (ENHA) PT Lowered to $5 at Canaccord
• Trump: Iran cannot have, in any way, shape, or form, a nuclear weapon
• Celcuity Inc (CELC) PT Raised to $175 at Guggenheim